Hologic (HOLX) to Release Quarterly Earnings on Thursday

Hologic (NASDAQ:HOLX) is set to announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.98 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. During the same period in the previous year, the firm posted $1.07 EPS. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Hologic Stock Performance

Shares of Hologic stock opened at $75.77 on Wednesday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic has a 1-year low of $64.02 and a 1-year high of $87.88. The company has a 50 day moving average of $76.08 and a 200-day moving average of $72.88. The company has a market cap of $17.79 billion, a PE ratio of 35.91, a price-to-earnings-growth ratio of 2.57 and a beta of 1.00.

Insider Buying and Selling

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HOLX. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. UBS Group increased their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Evercore ISI upped their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.